Pfizer's Vyndaqel approved in Europe as first treatment for TTR-FAP

Pfizer's Vyndaqel (tafamidis) has been approved in the EU as a treatment for transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.